Estudios clínicos

Arkansas Children’s, we are connected to international networks of researchers studying and developing the latest medical therapies. En muchos casos, podemos proporcionar tratamientos a su hijo aquí mismo en el campus. En algunos casos, podemos conectar a su hijo con tratamientos en desarrollo en un centro médico socio. To learn more about participating in a clinical trial, check out our Frequently Asked Questions.

  • Ewing Sarcoma at First Relapse sponsored by Gardalis – A Multi-Center Phase 3, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing Sarcoma
  • High-Risk Neuroblastoma at Initial Diagnosis sponsored by El Beat Childhood Cancer Consortium - PEDS-PLAN (Pediatric Precision Laboratory Advanced Neuroblastoma Therapy) A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma
  • Relapsed or Refractory Solid Tumors and Leukemia sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) -  A phase I study of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
  • High-Risk Hodgkin’s Lymphoma at Initial Diagnosis sponsored by Takeda - An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
  • Relapsed, Refractory, or Treatment-Naïve Severe Aplastic Anemia sponsored by Novartis -  A phase II, open-label, non-controlled, intra-patient dose escalation study to characterize the pharmacokinetics after oral administration of eltrombopag in pediatric patients with refractory, relapsed or treatment naïve severe aplastic anemia or recurrent aplastic anemia
  • Neuroblastoma in First Remission sponsored by El Beat Childhood Cancer Consortium - NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
  • The pan-ERBB inhibitor Neratinib in Previously Treated Solid and Brain Tumors sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase I Study for recurrent or refractory solid and brain tumors including:
  • MEK Inhibitor Cobimetnib in Previously Treated Solid Tumors (Study G029665) sponsored by Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) – a Phase 2 Study for Low-Grade Gliomas